# Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

> **NCT06807437** · PHASE3 · RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 274 (estimated)

## Conditions studied

- Pancreatic Carcinoma
- Pancreatic Neoplasm

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Distal Pancreatectomy
- **DRUG:** Lanreotide
- **OTHER:** Questionnaire Administration
- **OTHER:** Saline

## Key facts

- **NCT ID:** NCT06807437
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-09
- **Primary completion:** 2027-11-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 274 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06807437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06807437, "Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06807437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*